UNLABELLED: Previously, homozygous deletion of the UGT2B17 gene has shown association with hip fracture. Using a high-throughput qRT-PCR assay, we genotyped UGT2B17 copy number variation (CNV) in 1,347 elderly Caucasian women and examined for effects on bone phenotypes. We found no evidence of association between UGT2B17 CNV and osteoporosis risk in this population. INTRODUCTION: Genetic studies of osteoporosis commonly examine SNPs in candidate genes or whole genome analyses, but insertions and deletions of DNA, collectively called CNV, also comprise a large amount of the genetic variability between individuals. Previously, homozygous deletion of the UGT2B17 gene in CNV 4q13.2, which encodes an enzyme that mediates the glucuronidation of steroid hormones, has shown association with the risk of hip fracture. METHODS: We used a quantitative real-time PCR assay for genotyping the UGT2B17 CNV in a well-characterized population study of 1,347 Caucasian women aged 75.2 ± 2.7 years (mean ± SD), to assess the effect of the CNV on bone mass density (BMD) at the total hip site and osteoporosis risk. RESULTS: The UGT2B17 CNV distribution was consistent with the expected Hardy-Weinberg distribution and not different from frequencies previously reported in a Caucasian population. Data from ANCOVA of age- and weight-adjusted BMD for UGT2B17 CNV genotype showed no significant difference between genotype groups. Individuals with homozygous or heterozygous deletion of the UGT2B17 gene showed no increased risk of incident fragility fracture. CONCLUSIONS: These data suggest that quantitative real-time PCR is a rapid and efficient technique for determination of candidate CNVs, including the UGT2B17 CNV; however, we found no evidence of an effect of UGT2B17 CNV on osteoporosis risk in elderly Caucasian women.
UNLABELLED: Previously, homozygous deletion of the UGT2B17 gene has shown association with hip fracture. Using a high-throughput qRT-PCR assay, we genotyped UGT2B17 copy number variation (CNV) in 1,347 elderly Caucasian women and examined for effects on bone phenotypes. We found no evidence of association between UGT2B17 CNV and osteoporosis risk in this population. INTRODUCTION: Genetic studies of osteoporosis commonly examine SNPs in candidate genes or whole genome analyses, but insertions and deletions of DNA, collectively called CNV, also comprise a large amount of the genetic variability between individuals. Previously, homozygous deletion of the UGT2B17 gene in CNV 4q13.2, which encodes an enzyme that mediates the glucuronidation of steroid hormones, has shown association with the risk of hip fracture. METHODS: We used a quantitative real-time PCR assay for genotyping the UGT2B17 CNV in a well-characterized population study of 1,347 Caucasian women aged 75.2 ± 2.7 years (mean ± SD), to assess the effect of the CNV on bone mass density (BMD) at the total hip site and osteoporosis risk. RESULTS: The UGT2B17 CNV distribution was consistent with the expected Hardy-Weinberg distribution and not different from frequencies previously reported in a Caucasian population. Data from ANCOVA of age- and weight-adjusted BMD for UGT2B17 CNV genotype showed no significant difference between genotype groups. Individuals with homozygous or heterozygous deletion of the UGT2B17 gene showed no increased risk of incident fragility fracture. CONCLUSIONS: These data suggest that quantitative real-time PCR is a rapid and efficient technique for determination of candidate CNVs, including the UGT2B17 CNV; however, we found no evidence of an effect of UGT2B17 CNV on osteoporosis risk in elderly Caucasian women.
Authors: W James Kent; Charles W Sugnet; Terrence S Furey; Krishna M Roskin; Tom H Pringle; Alan M Zahler; David Haussler Journal: Genome Res Date: 2002-06 Impact factor: 9.043
Authors: D A Elson; G Thurston; L E Huang; D G Ginzinger; D M McDonald; R S Johnson; J M Arbeit Journal: Genes Dev Date: 2001-10-01 Impact factor: 11.361
Authors: Fernando Rivadeneira; Unnur Styrkársdottir; Karol Estrada; Bjarni V Halldórsson; Yi-Hsiang Hsu; J Brent Richards; M Carola Zillikens; Fotini K Kavvoura; Najaf Amin; Yurii S Aulchenko; L Adrienne Cupples; Panagiotis Deloukas; Serkalem Demissie; Elin Grundberg; Albert Hofman; Augustine Kong; David Karasik; Joyce B van Meurs; Ben Oostra; Tomi Pastinen; Huibert A P Pols; Gunnar Sigurdsson; Nicole Soranzo; Gudmar Thorleifsson; Unnur Thorsteinsdottir; Frances M K Williams; Scott G Wilson; Yanhua Zhou; Stuart H Ralston; Cornelia M van Duijn; Timothy Spector; Douglas P Kiel; Kari Stefansson; John P A Ioannidis; André G Uitterlinden Journal: Nat Genet Date: 2009-10-04 Impact factor: 38.330
Authors: Landry K Kamdem; Jingyue Xi; Brandi L Clark; Bryana J Gregory; Kelley M Kidwell; Ana-Maria Storniolo; Vered Stearns; Daniel F Hayes; Christina L Gersch; James M Rae; N Lynn Henry; Daniel L Hertz Journal: Breast Cancer Res Treat Date: 2019-02-12 Impact factor: 4.872
Authors: Haeyoung Zhang; Abdul Basit; Diana Busch; King Yabut; Deepak Kumar Bhatt; Marek Drozdzik; Marek Ostrowski; Albert Li; Carol Collins; Stefan Oswald; Bhagwat Prasad Journal: Biochem Pharmacol Date: 2018-08-04 Impact factor: 5.858
Authors: Shelby Chew; Zari Dastani; Suzanne J Brown; Joshua R Lewis; Frank Dudbridge; Nicole Soranzo; Gabriela L Surdulescu; J Brent Richards; Tim D Spector; Scott G Wilson Journal: Bone Date: 2012-08-02 Impact factor: 4.398